• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

甲型H1N1流感病毒疫苗中mOMV佐剂功效的评估。

Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine.

作者信息

Lee Byeong-Jae, Kwon Hyeok-Il, Kim Eun-Ha, Park Su-Jin, Lee Sang-Ho, Choi Young Ki, Kim Sang-Hyun

机构信息

College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Korea.

Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea.

出版信息

Clin Exp Vaccine Res. 2014 Jul;3(2):194-201. doi: 10.7774/cevr.2014.3.2.194. Epub 2014 Jun 20.

DOI:10.7774/cevr.2014.3.2.194
PMID:25003093
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4083072/
Abstract

PURPOSE

Since the pandemic (H1N1) 2009 virus has been a seasonal flu which still poses great human health concerns worldwide, vaccination would be considered as the most effective strategy to control the influenza virus spreading. Here, we assessed adjuvant efficacy of modified outer membrane vesicle (mOMV) towards the pandemic H1N1 split antigen.

MATERIALS AND METHODS

For this study, mice were vaccinated twice with various amount of antigen (0.05, 0.1, and 0.5 µg/dose hemagglutinin [HA]) that were mixed with mOMV, aluminum hydroxide (alum), and MF59, as well as the combined adjuvant comprising the mOMV plus alum.

RESULTS

We found that all the adjuvanted vaccines of A/California/04/09 (CA04, H1N1) containing HA antigen more than 0.1 µg/dose protected effectively from lethal challenge (maCA04, H1N1) virus, compared to the antigen only group. Furthermore, vaccinated mice received as low as 0.05 µg/dose of the split vaccine containing the combined adjuvant (10 µg of mOMV plus alum) showed a full protection against lethal challenge with H1N1 virus. Taken together, these results suggest that mOMV can exert not only the self-adjuvanticity but also a synergy effect for the vaccine efficacy when combined with alum.

CONCLUSION

Our results indicate that mOMV could be a promising vaccine adjuvant by itself and it could be used as a vaccine platform for development of various vaccine formulations to prepare future influenza pandemic.

摘要

目的

由于2009年甲型H1N1流感大流行病毒已成为一种季节性流感，仍在全球范围内对人类健康构成重大威胁，接种疫苗被认为是控制流感病毒传播的最有效策略。在此，我们评估了改良外膜囊泡（mOMV）对甲型H1N1流感裂解抗原的佐剂效果。

材料与方法

在本研究中，用不同剂量的抗原（0.05、0.1和0.5μg/剂量血凝素[HA]）对小鼠进行两次接种，这些抗原分别与mOMV、氢氧化铝（明矾）、MF59以及由mOMV加明矾组成的联合佐剂混合。

结果

我们发现，与仅含抗原的组相比，所有含有HA抗原且剂量超过0.1μg/剂量的A/加利福尼亚/04/09（CA04，H1N1）佐剂疫苗均能有效保护小鼠免受致死性攻击（maCA04，H1N）病毒感染。此外，接种低至含有联合佐剂（10μg mOMV加明矾）的0.05μg/剂量裂解疫苗的小鼠，对H1N1病毒的致死性攻击显示出完全保护作用。综上所述，这些结果表明mOMV不仅可以发挥自身佐剂作用，而且与明矾联合使用时对疫苗效力具有协同作用。

结论

我们的结果表明，mOMV本身可能是一种有前景的疫苗佐剂，并且可以用作疫苗平台来开发各种疫苗制剂，以应对未来的流感大流行。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d4/4083072/64d45fd5cfb5/cevr-3-194-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d4/4083072/3cf62ecf96a0/cevr-3-194-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d4/4083072/571008c6d022/cevr-3-194-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d4/4083072/64d45fd5cfb5/cevr-3-194-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d4/4083072/3cf62ecf96a0/cevr-3-194-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d4/4083072/571008c6d022/cevr-3-194-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d4/4083072/64d45fd5cfb5/cevr-3-194-g003.jpg

相似文献

1
Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine.甲型H1N1流感病毒疫苗中mOMV佐剂功效的评估。
Clin Exp Vaccine Res. 2014 Jul;3(2):194-201. doi: 10.7774/cevr.2014.3.2.194. Epub 2014 Jun 20.
2
Adjuvant efficacy of mOMV against avian influenza virus infection in mice.mOMV 对小鼠流感病毒感染的辅助疗效。
J Microbiol. 2013 Oct;51(5):682-8. doi: 10.1007/s12275-013-3411-3. Epub 2013 Oct 31.
3
Evaluating the Immune Response of Recombinant H1N1 Hemagglutinin with MF59 Adjuvant in Animal Model as a Novel Alternative to the Influenza Vaccine.评估 MF59 佐剂的重组 H1N1 血凝素在动物模型中的免疫反应，作为流感疫苗的新型替代品。
Iran J Allergy Asthma Immunol. 2020 Oct 18;19(5):497-508. doi: 10.18502/ijaai.v19i5.4465.
4
A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.一项评估 MF59（®）佐剂和非佐剂 A/H1N1 大流行流感疫苗在年轻到中年和老年人群中的安全性、免疫原性和接种一年后抗体持久性的剂量范围研究。
Hum Vaccin Immunother. 2014;10(8):2395-407. doi: 10.4161/hv.29393.
5
A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.一项针对老年人的剂量范围研究，以比较皮内和肌肉注射MF59®佐剂和非佐剂季节性流感疫苗后的安全性和免疫原性特征。
Hum Vaccin Immunother. 2014;10(6):1701-10. doi: 10.4161/hv.28618. Epub 2014 Apr 14.
6
Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.MF59佐剂A/H1N1大流行性流感疫苗在3至17岁儿童中的安全性和免疫原性。
Vaccine. 2015 Jan 1;33(1):174-81. doi: 10.1016/j.vaccine.2014.10.085. Epub 2014 Nov 11.
7
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.中国 2009 年甲型 H1N1 流感疫苗的安全性和免疫原性：一项多中心、双盲、随机、安慰剂对照试验。
Lancet. 2010 Jan 2;375(9708):56-66. doi: 10.1016/S0140-6736(09)62003-1. Epub 2009 Dec 15.
8
Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.鉴定抗原和佐剂剂量，使儿童 3 至 < 9 岁人群在接种大流行性 A/H1N1 流感疫苗后 1 年内获得最佳免疫原性和抗体持久性。
Pediatr Infect Dis J. 2012 Apr;31(4):e59-65. doi: 10.1097/INF.0b013e31824b9545.
9
AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.佐剂和非佐剂的 2009 年甲型流感（H1N1）疫苗在季节性流感疫苗接种和未接种的小鼠中诱导强烈的抗体反应。
Vaccine. 2010 Apr 19;28(18):3076-9. doi: 10.1016/j.vaccine.2010.02.050. Epub 2010 Mar 1.
10
A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.基于改良安卡拉痘苗病毒的甲型 H1N1 流感活疫苗具有高度免疫原性，并在主动和被动免疫中保护小鼠。
PLoS One. 2010 Aug 16;5(8):e12217. doi: 10.1371/journal.pone.0012217.

引用本文的文献

1
Salvia miltiorrhiza polysaccharide-Mn²⁺-PLGA as an adjuvant in H9N2 vaccine: Immunomodulatory effects in chickens.丹参多糖-Mn²⁺-聚乳酸-羟基乙酸共聚物作为H9N2疫苗的佐剂：对鸡的免疫调节作用
Poult Sci. 2025 Jul 26;104(10):105599. doi: 10.1016/j.psj.2025.105599.
2
Combining Intramuscular and Intranasal Immunization With the MF59-Adjuvanted Respiratory Syncytial Virus Pre-Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice.将肌内注射和鼻内免疫与MF59佐剂呼吸道合胞病毒预融合蛋白亚单位疫苗相结合可在小鼠中诱导强大的体液免疫和细胞免疫反应。
MedComm (2020). 2025 Jul 15;6(8):e70301. doi: 10.1002/mco2.70301. eCollection 2025 Aug.
3

本文引用的文献

1
Adjuvant efficacy of mOMV against avian influenza virus infection in mice.mOMV 对小鼠流感病毒感染的辅助疗效。
J Microbiol. 2013 Oct;51(5):682-8. doi: 10.1007/s12275-013-3411-3. Epub 2013 Oct 31.
2
An overview of the recent outbreaks of the avian-origin influenza A (H7N9) virus in the human.人感染禽流感 H7N9 病毒近期疫情概述。
J Chin Med Assoc. 2013 May;76(5):245-8. doi: 10.1016/j.jcma.2013.04.003. Epub 2013 May 4.
3
Impact of influenza A(H1N1)pdm09 virus on circulation dynamics of seasonal influenza strains in Kenya.
Testing GMMA with and without Aluminium Salt-Based Adjuvants in Animal Models.
在动物模型中对含和不含铝盐佐剂的GMMA进行测试。
Pharmaceutics. 2024 Apr 22;16(4):568. doi: 10.3390/pharmaceutics16040568.
4
Bacterial extracellular vesicles control murine norovirus infection through modulation of antiviral immune responses.细菌细胞外囊泡通过调节抗病毒免疫应答来控制鼠诺如病毒感染。
Front Immunol. 2022 Aug 4;13:909949. doi: 10.3389/fimmu.2022.909949. eCollection 2022.
5
OMV Vaccines and the Role of TLR Agonists in Immune Response.OMV 疫苗和 TLR 激动剂在免疫应答中的作用。
Int J Mol Sci. 2020 Jun 21;21(12):4416. doi: 10.3390/ijms21124416.
6
Bacillus subtilis spores as adjuvants against avian influenza H9N2 induce antigen-specific antibody and T cell responses in White Leghorn chickens.枯草芽孢杆菌孢子作为抗禽流感 H9N2 的佐剂诱导白来航鸡产生抗原特异性抗体和 T 细胞应答。
Vet Res. 2020 May 24;51(1):68. doi: 10.1186/s13567-020-00788-8.
7
Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.使用甘露聚糖肽作为新型佐剂的鼻内免疫接种用于灭活流感疫苗及其与MF59相比的佐剂效果
PLoS One. 2017 Jan 4;12(1):e0169501. doi: 10.1371/journal.pone.0169501. eCollection 2017.
8
Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model.携带修饰脂质A部分的外膜囊泡增强了流感疫苗在小鼠模型中的功效，该疫苗表现出降低的内毒素毒性。
Vaccine. 2017 Jan 23;35(4):586-595. doi: 10.1016/j.vaccine.2016.12.025. Epub 2016 Dec 23.
甲型 H1N1pdm09 流感病毒对肯尼亚季节性流感株循环动态的影响。
Am J Trop Med Hyg. 2013 May;88(5):940-5. doi: 10.4269/ajtmh.12-0147. Epub 2013 Mar 4.
4
The first, second and third wave of pandemic influenza A (H1N1)pdm09 in North Denmark Region 2009-2011: a population-based study of hospitalizations.2009-2011 年丹麦北日德兰地区甲型流感 A（H1N1）pdm09 的第一、二、三波流行：基于人群的住院研究。
Influenza Other Respir Viruses. 2013 Sep;7(5):776-82. doi: 10.1111/irv.12093. Epub 2013 Feb 9.
5
Seroepidemiologic effects of influenza A(H1N1)pdm09 in Australia, New Zealand, and Singapore.澳大利亚、新西兰和新加坡的甲型 H1N1pdm09 流感血清流行病学效应。
Emerg Infect Dis. 2013 Jan;19(1):92-101. doi: 10.3201/eid1901.111643.
6
WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011.世界卫生组织推荐用于 2012 年南半球流感疫苗的病毒：2011 年 2 月至 9 月采集的甲型 H1N1pdm09、甲型 H3N2 和乙型流感病毒的流行病学、抗原性和遗传学特征。
Vaccine. 2012 Oct 5;30(45):6461-71. doi: 10.1016/j.vaccine.2012.07.089. Epub 2012 Aug 20.
7
Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.AS03 佐剂 A(H1N1)pmd09 疫苗与季节性三价疫苗同时或序贯接种于 61 岁及以上成年人的安全性和免疫原性：两项多中心随机试验数据。
Vaccine. 2012 Oct 5;30(45):6483-91. doi: 10.1016/j.vaccine.2012.07.081. Epub 2012 Aug 9.
8
Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.在健康成年人和老年人中，使用和不使用 AS03 佐剂系统的不同剂量单价 2009 年 H1N1 流感疫苗的免疫原性和安全性。
J Infect Dis. 2012 Sep 15;206(6):811-20. doi: 10.1093/infdis/jis427. Epub 2012 Jul 10.
9
Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.随机临床试验免疫原性和安全性的一种重组 H1N1/2009 大流行性流感疫苗含有 Advax™多糖佐剂。
Vaccine. 2012 Aug 3;30(36):5407-16. doi: 10.1016/j.vaccine.2012.06.009. Epub 2012 Jun 17.
10
The mechanism of action of MF59 - an innately attractive adjuvant formulation.MF59 的作用机制 - 一种先天具有吸引力的佐剂配方。
Vaccine. 2012 Jun 19;30(29):4341-8. doi: 10.1016/j.vaccine.2011.09.061.